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Targeting the Renin–Angiotensin System
The renin–angiotensin system (RAS) has long been
recognized as an important mediator in the progression
of chronic renal failure. Traditionally, the RAS has been
considered as an endocrine system. In this view, the
glycoprotein angiotensinogen, produced in the liver, is
cleaved by renin, which is released from renal
juxtaglomerular cells. Thus, angiotensin (Ang) I is
generated, which in turn is converted by the high
angiotensin converting enzyme (ACE) activity of the
lungs into the active substance Ang II. Recently, it has
become apparent that indeed the system is much more
complex. Genes encoding for renin, angiotensinogen,
and ACE are detected in the human kidney [1]. There
are two main Ang II receptors (AT1R and AT2R) in
humans, and these receptors are detected in the
vasculature, glomeruli and tubular segments [2]. Almost
all classic Ang II-associated functions such as
vasoconstriction, aldosterone release, stimulation of
tubular transport, proinflammatory effects as well as
profibrogenic and growth stimulatory actions are
mediated by AT1R [3]. The function of the AT2R is
less clear, but it has been proposed that activation of
this receptor antagonizes those functions which are
mediated by AT1R, providing a negative feedback
control. Along this line, it has been shown that activation
of AT2R decreases blood pressure through release of
nitric oxide, inhibits growth and induces differentiation,
and even mediates apoptosis [4]. Recent evidence,
however, indicates that cell hypertrophy and
proinflammatory effects can also be transduced by
AT2R activation under certain conditions [5].
Pharmacologic blockade of the RAS, either by
ACE inhibitor (ACEI) or AT1R antagonist, retards
progression of chronic kidney disease [6]. Yet, neither
monotherapy with an ACEI nor an AT1R antagonist
is able to completely prevent end-stage renal disease.
Recently, the concept has been introduced that
combination therapy (i.e. coadministration of an ACEI
and an AT1R antagonist) is superior to the respective
monotherapies. Although such combination may at
first sight seem redundant, a sound pathophysiologic
rationale can be offered to justify the use of com-
bination therapy. As nephrologists, we are fully aware
that not all patients treated with ACEI or AT1R
antagonist show a satisfactory antiproteinuric
response. An insufficient response to ACE inhibition
might be explained by incomplete blockade because
at least 40% of Ang II is produced via other non-ACE
pathways, such as chymase that is chiefly synthesized
in mast cells [7]. This incomplete blockade possibly
explains the observation that plasma Ang II levels
return to normal after chronic ACEI treatment, the
ACE escape phenomenon. On the other hand,
monotherapy with AT1R antagonist may induce high
Ang II concentrations because of interruption of
negative feedback at the juxtaglomerular apparatus
and stimulation by Ang II of AT2R with activation of
pathophysiologic pathways including apoptosis [4],
nuclear factor-κB activation, and the induction of
chemokines [8,9].
The COOPERATE trial [10] was the first long-term
clinical study to address the effect of dual blockade on
primary renal endpoints. This was a double-blind,
randomized, controlled study of 263 Japanese patients
with nondiabetic proteinuric renal disease that was
carried out in a single center. Patients were treated with
trandolapril, losartan, or both drugs. The initial
projected follow-up was 5 years, but the study was
terminated prematurely after an interim analysis at
3 years showed that 23% of those who were on
monotherapy reached the combined endpoint of
doubling serum creatinine or creatinine clearance < 7
mL/min, compared with only 11% of those on dual
blockade. Obviously, it remains unclear whether similar
benefits of combination therapy would be applicable
to patients with diabetic nephropathy, as the
COOPERATE study excluded diabetic subjects.
In this issue of the Hong Kong Journal of
Nephrology, Saito et al [11] evaluated combination
ACEI and AT1R antagonist therapy in diabetic
nephropathy. Thirty-four subjects with macro-
albuminuria were included, 16 of whom were
treated with imidapril, 8 were given losartan con-
secutive to imidapril, and 10 received imidapril con-
secutive to losartan. After a follow-up of 6 months,
losartan enhanced the antiproteinuric response of
imidapril significantly, although the addition of
imidapril to losartan did not further reduce proteinuria.
The authors concluded that AT1R antagonists have a
dominant antiproteinuric effect over ACEI as chronic
administration of the latter could lead to an escape
phenomenon as alluded to above, while the efficacy
of AT1R antagonists remains the same even if ACEI
is added as the increase in Ang II cannot exert any
effect on AT1R due to the presence of its specific
blocker. However, the authors have overlooked the
potential action of Ang II on AT2R, which could also
mediate inflammation, fibrosis, and apoptosis [4,8,9],
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and the fact that increased Ang II due to interruption of
negative feedback by the AT1R blocker will increase
its conversion to Ang IV which binds to AT4R and
mediates, at least in experimental settings, profibrogenic
effects that are not antagonized by AT1R blockers [12].
There are two other major flaws in this study. First,
there was an imbalance in blood pressure control
among the various groups, which becomes a serious
confounder. Secondly, the patient number is small in
each group and the risk of overfitting must not be
overlooked. Finally, the observation period of only 6
months is far too short to justify the conclusion that
adding AT1R blocker to ACEI therapy augments a
protective effect against the progression of diabetic
nephropathy. Indeed, a recent meta-analysis [13] of
156 diabetic nephropathy subjects showed that
although combination therapy reduces proteinuria to
a greater extent than ACEI alone, most of the included
studies were of short duration (8–12 weeks), and the
few long-term studies (12 months) have not
demonstrated benefit. Clearly, there is a need for more
long-term and carefully designed clinical trials to
address the potential benefits of ACEI plus AT1R
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